Table II.
Risk profile of the included patients
| Author | Mean age, years | Varicose veins, no. (%) | History of SVT, no. (%) | History of DVT/PE, no. (%) | Family history of VTE, no. (%) | Cancer, no. (%) | Thrombophilia, no. (%) |
|---|---|---|---|---|---|---|---|
| Marchiori et al, 200218 | 62 | 37 (61.7%) | 9 (15.0%) | 7 (11.7%) | N/A | 5 (8.3%) | N/A |
| STENOX, 200319 | 62 | N/A | N/A | 62 (14.5%) | N/A | 6 (1.4%) | N/A |
| Lozano et al, 200320 | 59 | 49 (81.7%) | 29 (48.3%) | N/A | N/A | N/A | N/A |
| Prandoni et al (VESALIO), 200521 | 63 | 100 (61.0%) | N/A | N/A | N/A | N/A | N/A |
| Decousus et al (CALISTO), 201022 | 57 | 2660 (88.6%) | 356 (11.9%) | 209 (7.0%) | N/A | 61 (2.0%) | 38 (1.3%) |
| Rathbun et al, 201223 | 51 | 32 (44.4%) | 7 (9.7%) | 5 (6.9%) | N/A | 7 (9.7%) | N/A |
| Cosmi et al (STEFLUX), 201224 | 63 | 498 (75.0%) | 191 (28.8%) | 58 (8.7%) | 78 (11.7%) | N/A | 31 (4.7%) |
| Spirkoska et al, 201525 | 60 | 0 (0%) | N/A | N/A | N/A | 3 (5.0%) | N/A |
| Beyer-Westendorf et al (SURPRISE), 201739 | 61 | 330 (69.9%) | 229 (48.5%) | N/A | 55 (11.7%) | N/A | |
| Kearon C et al, 202026 | 59 | 58 (68.2%) | 25 (19.4%) | 8 (9.4%) | N/A | 2 (2.4%) | N/A |
| Ascer et al, 199527 | 63 | 10 (50.0%) | 4 (20.0%) | 0 (0%) | N/A | N/A | N/A |
| Gorty et al, 200428 | 52 | 48 (80.0%) | 24 (40.0%) | 10 (16.7%) | N/A | 4 (6.7%) | 12 (20.0%) |
| Decousus et al (POST), 20105 | 65 | 690 (81.8%) | 285 (33.8%) | 120 (14.2%) | 206 (24.4%) | 93 (11.0%) | 48 (5.7%) |
| Sartori et al, 201629 | 65 | 430 (63.4%) | N/A | N/A | N/A | 36 (5.3%) | N/A |
| Samuelson et al, 201630 | 59 | 85 (23.7%) | N/A | 12 (3.3%) | N/A | 29 (8.1%) | N/A |
| Blin et al, 201731 | 65 | 843 (86.2%) | 400 (40.9%) | 196 (20.0%) | N/A | 95 (9.7%) | 23 (2.4%) |
| Barco et al (ICARO), 201732 | 54 | 140 (34.1%) | 153 (37.2%) | 68 (16.5%) | 129 (31.4%) | 29 (7.1%) | N/A |
| Gouveia et al, 201833 | 51 | 43 (71.7%) | 7 (11.7%) | 21 (35.0%) | 4 (6.7%) | 0 (0%) | 2 (3.3%) |
| Geersing et al, 20183 | 56 | 782 (38.9%) | N/A | N/A | N/A | 81 (94.0%) | N/A |
| Karathanos et al (SeVEN), 202134 | 59 | 436 (66.1%) | 187 (28.3%) | 34 (5.2%) | 91 (13.8%) | 10 (1.5%) | N/A |
| Karathanos C et al (SeVEN), 202335 | 59 | 601 (62.9%) | 256 (26.8%) | 48 (5.0%) | 93 (9.7%) | 3 (0,3%) | N/A |
| Clapham R et al, 202236 | 61 | 41 (75.9%) | 9 (16.7%) | 16 (29.6%) | 8 (14.8%) | 1 (1.9%) | 1 (1.9%) |
| Casian D et al, 202237 | 60 | 104 (54.7%) | N/A | N/A | N/A | N/A | N/A |
| Rabe E et al (INSIGHTS-SVT), 202338 | 61 | 698 (80.0%) | 278 (31.9%) | 148 (17.0%) | 145 (16.6%) | 63 (7.2%) | 50 (5.7%) |
DVT, Deep vein thrombosis; N/A, not available; PE, pulmonary embolism; SVT, superficial vein thrombosis; VTE, venous thromboembolism.